Zachary C Bitan1, Alice Zhou1, Donald J McMahon1, Debra Kessler2, Beth H Shaz2, Elise Caccappolo3, Joseph Schwartz1, Richard O Francis1, Gary M Brittenham4, Steven L Spitalnik1, Eldad A Hod1. 1. Pathology and Cell Biology, Columbia University Irving Medical Center, Presbyterian Hospital, New York, NY, United States of America. 2. New York Blood Center, New York, NY, United States of America. 3. Cognitive Neuroscience Division, Department of Neurology, Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Irving Medical Center, New York, NY, United States of America. 4. Pediatrics, Columbia University Irving Medical Center-New York Presbyterian Hospital, New York, NY, United States of America.
Abstract
BACKGROUND: Despite fulfilling all requirements for blood donation, a large proportion of regular blood donors are iron deficient. Red blood cells (RBC) from iron-deficient donors may be particularly susceptible to damage induced by standard refrigerated storage. Herein, we present a study protocol for testing whether correcting iron deficiency in donors with iron-deficient erythropoiesis will improve the quality of their refrigerator-stored RBC. MATERIALS AND METHODS: This is a randomised, controlled, double-blind clinical trial. Sixty healthy regular donors who meet donation standards, while exhibiting iron-deficient erythropoiesis by laboratory testing criteria, will donate a single standard RBC unit that will be leucoreduced and stored in a refrigerator under standard conditions for 40-42 days. A 51Cr-radiolabelled 24-hour RBC recovery study will be performed and then these donors will be randomised to receive, in a double-blinded fashion, either intravenous saline, as a control, or low-molecular weight iron dextran (1 g), to provide total iron repletion. Four to six months later, they will donate a second RBC unit, which will be similarly stored, and autologous 51Cr-labelled 24-hour post-transfusion RBC recovery will again be determined. RESULTS: The primary endpoint will be the change in 24-hour post-transfusion recovery from the first to the second donation. The primary outcome will be the group mean difference in the primary endpoints between the group receiving intravenous saline and the group receiving intravenous iron dextran. Secondary outcomes will be quality of life, fatigue, and emotional health, assessed by surveys. CONCLUSION: This study will provide definitive evidence as to whether donor iron deficiency affects the quality of the blood supply and will assess the severity of symptoms affecting iron-deficient blood donors.
RCT Entities:
BACKGROUND: Despite fulfilling all requirements for blood donation, a large proportion of regular blood donors are iron deficient. Red blood cells (RBC) from iron-deficient donors may be particularly susceptible to damage induced by standard refrigerated storage. Herein, we present a study protocol for testing whether correcting iron deficiency in donors with iron-deficient erythropoiesis will improve the quality of their refrigerator-stored RBC. MATERIALS AND METHODS: This is a randomised, controlled, double-blind clinical trial. Sixty healthy regular donors who meet donation standards, while exhibiting iron-deficient erythropoiesis by laboratory testing criteria, will donate a single standard RBC unit that will be leucoreduced and stored in a refrigerator under standard conditions for 40-42 days. A 51Cr-radiolabelled 24-hour RBC recovery study will be performed and then these donors will be randomised to receive, in a double-blinded fashion, either intravenous saline, as a control, or low-molecular weight iron dextran (1 g), to provide total iron repletion. Four to six months later, they will donate a second RBC unit, which will be similarly stored, and autologous 51Cr-labelled 24-hour post-transfusion RBC recovery will again be determined. RESULTS: The primary endpoint will be the change in 24-hour post-transfusion recovery from the first to the second donation. The primary outcome will be the group mean difference in the primary endpoints between the group receiving intravenous saline and the group receiving intravenous iron dextran. Secondary outcomes will be quality of life, fatigue, and emotional health, assessed by surveys. CONCLUSION: This study will provide definitive evidence as to whether donoriron deficiency affects the quality of the blood supply and will assess the severity of symptoms affecting iron-deficient blood donors.
Authors: Richard O Francis; Sonia Mahajan; Francesca Rapido; Francesca La Carpia; Mark Soffing; Chaitanya Divgi; Randy Yeh; Akiva Mintz; Lenhurst Leslie; Irina Agrest; Matthew S Karafin; Yelena Ginzburg; Beth H Shaz; Steven L Spitalnik; Joseph Schwartz; Tiffany Thomas; Xiaoyun Fu; Pascal Amireault; Pierre Buffet; James C Zimring; Angelo D'Alessandro; Eldad A Hod Journal: Transfusion Date: 2019-04-19 Impact factor: 3.157
Authors: Lee Wong; Samuel Smith; Marisa Gilstrop; Richard Derman; Sarah Auerbach; Nicola London; Steven Lenowitz; Huzefa Bahrain; Jessica McClintock; Michael Auerbach Journal: Am J Hematol Date: 2016-04-13 Impact factor: 10.047
Authors: Alison O Booth; Karen Lim; Hugh Capper; David Irving; Jenny Fisher; Sarah A McNaughton; Lynn Riddell; Anthony Keller; Caryl A Nowson Journal: Transfusion Date: 2013-07-22 Impact factor: 3.157
Authors: A Mireille Baart; Paulus A H van Noord; Yvonne Vergouwe; Karel G M Moons; Dorine W Swinkels; Erwin T Wiegerinck; Wim L A M de Kort; Femke Atsma Journal: Transfusion Date: 2012-11-26 Impact factor: 3.157
Authors: Sophie Waldvogel; Baptiste Pedrazzini; Paul Vaucher; Raphael Bize; Jacques Cornuz; Jean-Daniel Tissot; Bernard Favrat Journal: BMC Med Date: 2012-01-24 Impact factor: 8.775